Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report
| Autor: | Hong‑Ge Wu, Dan‑Dan Yu, Jing Cheng, Yi‑Chen Liang, Gang Wu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
medicine.medical_specialty Pathology Nausea Asymptomatic Gastroenterology Gefitinib Internal medicine Carcinoma Medicine heterocyclic compounds Epidermal growth factor receptor Adverse effect skin and connective tissue diseases Stomatitis neoplasms biology business.industry Cancer Articles medicine.disease respiratory tract diseases Oncology biology.protein medicine.symptom business medicine.drug |
| Popis: | Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dermatological reactions are the most common adverse events associated with gefitinib treatment; other adverse effects, including diarrhea, nausea, stomatitis and an asymptomatic elevation of liver enzymes have also been reported. The present study describes a patient with intestinal obstruction who was successfully undergoing treatment with gefitinib for primary and metastatic neoplasms. Gefitinib-induced intestinal obstruction has not been previously reported; therefore, careful monitoring of gastrointestinal symptoms should be conducted throughout the course of gefitinib-treated malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|